Publications by authors named "R Verheijen"
Article Synopsis
- A Phase III study tested the efficacy of subcutaneous versus intravenous amivantamab for patients with advanced non-small cell lung cancer (NSCLC) who had progression after prior treatments.
- Results showed that the subcutaneous form maintained efficacy, with fewer side effects and a significantly longer overall survival, while also being more convenient to administer.
- Patients receiving subcutaneous amivantamab had less infusion-related reactions and faster administration times, with 85% finding the treatment convenient compared to only 35% in the intravenous group.
Objectives: To describe the perceived importance of suggested hamstring injury risk factors according to chief medical officers (CMOs) of European male professional football clubs. A secondary objective was to compare if these perceptions differed between teams with a lower-than-average hamstring injury burden and teams with a higher than average hamstring injury burden.
Methods: First, CMOs of 15 European professional male football clubs were asked to suggest risk factors for hamstring injury in their club.
Correlations between increasing concentrations of circulating tumor DNA (ctDNA) in plasma and disease progression have been shown. A nonlinear mixed effects model to describe the dynamics of epidermal growth factor receptor (EGFR) ctDNA data from patients with non-small cell lung cancer (NSCLC) combined with a parametric survival model were developed to evaluate the ability of these modeling techniques to describe ctDNA data. Repeated ctDNA measurements on L858R, exon19del, and T790M mutants were available from 54 patients with EGFR mutated NSCLC treated with erlotinib or gefitinib.
View Article and Find Full Text PDFBackground: Most patients with cancer treated with everolimus experience stomatitis, which seriously affects the quality of life. The salivary concentrations of everolimus may predict the incidence and severity of stomatitis. The authors aimed to examine whether it was feasible to quantify the everolimus concentration in saliva and subsequently use it to predict stomatitis.
View Article and Find Full Text PDFBackground: The European Society of Gynaecological Oncology (ESGO) and partners are committed to improving the training for gynecologic oncology fellows. The aim of this survey was to assess the type and level of training in cervical cancer surgery and to investigate whether the Laparoscopic Approach to Cervical Cancer (LACC) trial results impacted training in radical surgery for gynecologic oncology fellows.
Methods: In June 2020, a 47-question electronic survey was shared with European Network of Young Gynaecologic Oncologists (ENYGO) members.